NEW YORK--(BUSINESS WIRE)--Jefferies today announced the appointment of Biren Amin as a Managing Director and Senior Equity Research Analyst covering Biotechnology companies.
Steven R. Black, Global Head of Equity Research at Jefferies, commented, “We are pleased to welcome Biren as a valuable addition to our global research effort in healthcare, which is a focus area for our firm and a critical segment of the global economy. Biren’s significant experience and expertise will further extend our leading healthcare research franchise and add immediate value to our equity offering to institutional investors.”
Mr. Amin complements Jefferies’ existing global Healthcare equity research practice, which is comprised of 19 Research Analysts covering 246 companies in the Biotechnology, Pharmaceuticals, Healthcare REITs, Healthcare Services, Life Sciences, Diagnostic Tools, Medical Supplies, Medical Devices and Specialty Pharmaceuticals industries.
Jefferies and its affiliates have more than 250 equity research professionals in the U.S., Europe and Asia covering nearly 1300 companies in the areas of aerospace & defense, clean technology, consumer, energy, financial services, gaming, lodging & leisure, healthcare, industrials, maritime, media & entertainment, real estate, technology, telecommunications and utilities.
Mr. Amin brings to Jefferies more than 15 years of industry experience, and joins the firm from WJB Capital Group, where he was an Equity Research Analyst. Previously, he was a Biotechnology Analyst at FTN Equity Markets, and held similar Equity Research roles at Stanford Financial and Prudential Equity Group. Previously, he worked in Corporate Development at Aventis Pharmaceuticals. He received an MBA from the Stern School of Business at New York University and a MS in Pharmacy from Long Island University.
Jefferies Group, Inc. (NYSE: JEF), a global securities and investment banking firm, has served companies and investors for nearly 50 years.